Literature DB >> 23070727

Iron accumulation in Parkinson's disease.

Hideki Mochizuki1, Toru Yasuda.   

Abstract

Although the exact cause of Parkinson's disease (PD) is still unknown, recent interest has been focused on the role of iron in the nigral cell death in PD. Several studies have shown that a selective and significant elevation in iron occurs in the substantia nigra of patients with PD. However, the mechanisms involved in iron accumulation also remain unclear. In this article, we describe recent findings regarding the mechanisms and potential toxic effects of iron accumulation in hereditary and sporadic PD and animal models of PD, including our genetic mouse model of PD. The review provides an opportunity to revisit the possible roles of iron accumulation in the pathogenic cascade(s) of PD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23070727     DOI: 10.1007/s00702-012-0905-9

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  40 in total

1.  The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.

Authors:  N Ostrerova-Golts; L Petrucelli; J Hardy; J M Lee; M Farer; B Wolozin
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

2.  Increased nigral iron content in postmortem parkinsonian brain.

Authors:  D T Dexter; F R Wells; F Agid; Y Agid; A J Lees; P Jenner; C D Marsden
Journal:  Lancet       Date:  1987-11-21       Impact factor: 79.321

3.  Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure.

Authors:  V N Uversky; J Li; A L Fink
Journal:  J Biol Chem       Date:  2001-09-11       Impact factor: 5.157

4.  Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys.

Authors:  H Mochizuki; H Imai; K Endo; K Yokomizo; Y Murata; N Hattori; Y Mizuno
Journal:  Neurosci Lett       Date:  1994-02-28       Impact factor: 3.046

5.  Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease.

Authors:  D T Dexter; F R Wells; A J Lees; F Agid; Y Agid; P Jenner; C D Marsden
Journal:  J Neurochem       Date:  1989-06       Impact factor: 5.372

6.  Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.

Authors:  Luigi Zecca; Luigi Casella; Alberto Albertini; Chiara Bellei; Fabio A Zucca; Mireille Engelen; Andrzej Zadlo; Grzegorz Szewczyk; Mariusz Zareba; Tadeusz Sarna
Journal:  J Neurochem       Date:  2008-07-04       Impact factor: 5.372

7.  Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain.

Authors:  E Sofic; P Riederer; H Heinsen; H Beckmann; G P Reynolds; G Hebenstreit; M B Youdim
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

8.  Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys.

Authors:  Yi He; Patricia S Thong; Timothy Lee; S K Leong; Bo Y Mao; Fang Dong; Frank Watt
Journal:  Free Radic Biol Med       Date:  2003-09-01       Impact factor: 7.376

9.  Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  Tsuyoshi Furuya; Hideki Hayakawa; Masanori Yamada; Kenji Yoshimi; Shin Hisahara; Masayuki Miura; Yoshikuni Mizuno; Hideki Mochizuki
Journal:  J Neurosci       Date:  2004-02-25       Impact factor: 6.167

Review 10.  Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease.

Authors:  Manfred Gerlach; Kay L Double; Dorit Ben-Shachar; Luigi Zecca; Moussa B H Youdim; Peter Riederer
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

View more
  19 in total

Review 1.  Mitochondrial metals as a potential therapeutic target in neurodegeneration.

Authors:  A Grubman; A R White; J R Liddell
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 2.  Coherent and Contradictory Facts, Feats and Fictions Associated with Metal Accumulation in Parkinson's Disease: Epicenter or Outcome, Yet a Demigod Question.

Authors:  Mohd Sami Ur Rasheed; Sonam Tripathi; Saumya Mishra; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2016-08-01       Impact factor: 5.590

Review 3.  In vivo Cell Tracking Using Non-invasive Imaging of Iron Oxide-Based Particles with Particular Relevance for Stem Cell-Based Treatments of Neurological and Cardiac Disease.

Authors:  Markus Aswendt; Jean-Luc Boulland; Jasna Lojk; Stefan Stamenković; Joel C Glover; Pavle Andjus; Fabrizio Fiori; Mathias Hoehn; Dinko Mitrecic; Mojca Pavlin; Stefano Cavalli; Caterina Frati; Federico Quaini
Journal:  Mol Imaging Biol       Date:  2020-12       Impact factor: 3.488

Review 4.  Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders.

Authors:  Dharmendra Kumar Khatri; Amey Kadbhane; Monica Patel; Shweta Nene; Srividya Atmakuri; Saurabh Srivastava; Shashi Bala Singh
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-04-08

5.  Manganese efflux in Parkinsonism: insights from newly characterized SLC30A10 mutations.

Authors:  Margaret R DeWitt; Pan Chen; Michael Aschner
Journal:  Biochem Biophys Res Commun       Date:  2013-01-26       Impact factor: 3.575

6.  Effects of Environmental Pollutants on Cellular Iron Homeostasis and Ultimate Links to Human Disease.

Authors:  Dina M Schreinemachers; Andrew J Ghio
Journal:  Environ Health Insights       Date:  2016-03-07

7.  Downregulation of thioredoxin reductase 1 expression in the substantia nigra pars compacta of Parkinson's disease mice.

Authors:  Zihua Liu; Yuhong Jing; Jie Yin; Jiying Mu; Tingting Yao; Liping Gao
Journal:  Neural Regen Res       Date:  2013-12-15       Impact factor: 5.135

Review 8.  Desferrithiocin: a search for clinically effective iron chelators.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti
Journal:  J Med Chem       Date:  2014-09-10       Impact factor: 7.446

Review 9.  Parkinson's Disease: The Mitochondria-Iron Link.

Authors:  Yorka Muñoz; Carlos M Carrasco; Joaquín D Campos; Pabla Aguirre; Marco T Núñez
Journal:  Parkinsons Dis       Date:  2016-05-17

Review 10.  Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG).

Authors:  Neha Atulkumar Singh; Abul Kalam Azad Mandal; Zaved Ahmed Khan
Journal:  Nutr J       Date:  2016-06-07       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.